Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US

We evaluated the cost-effectiveness of prophylaxis with rVWF versus with pdVWF for patients with severe VWD. We found that rVWF is a cost-saving factor replacement compared to pdVWF across all willingness-to-pay thresholds in the United …